Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Neumora Therapeutics › Officer exercised or converted 22K NMRA derivative securities Insider trades
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Aug 20, 2026
Reporting period Not applicable
Filed with the SEC Aug 21, 2026 Officer Indirect holding Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
0001610717-26-000385
Filed / recorded Aug 21, 2026, 11:10 PM UTC
Added to OQRO Oct 8, 2026, 1:28 AM UTC
Data quality Verified: identifiers matched exactly
Issuer Neumora Therapeutics, Inc.
Reporting person Daljit Singh Aurora
Table Non-derivative (Table I)
Transaction date Aug 20, 2026
Acquired / disposed Acquired (A)
Ownership form Indirect — See footnote
Footnotes from the filing Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
Around the same time Insider filing
Traded Aug 20 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Insider selling
Traded Aug 20 · filed 1 day later Not reported under a pre-arranged trading plan
Neumora Therapeutics 's See Remarks sold $103K of Neumora Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Insider filing
Traded Aug 20 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 14, 2026 Company filing · Form 8-K · Results, Executive change Changed a top executive or board member, and reported its results “On August 14, 2026, the Company announced that Paul L. Berns, the Company’s current Chief Executive Officer, will become the Company’s Executive Chairperson of the Board of Directors (the “Board”), and Joshua Pinto, Ph.D., the Company’s current President, will succeed Mr. Berns as the Company’s Chief Executive Officer (the “Leadership Transition”) effective August 14, 2026 (the “Transition Date”).” Aug 17, 2026 Insider · 1 person Insiders: 3 sales (~$220K) Aug 18, 2026 Insider · 1 person Insiders: 2 sales (~$110K) Aug 19, 2026 Insider · 1 person Insiders: 2 sales (~$102K) Aug 20, 2026 Insider · 1 person Insiders: 2 sales (~$204K) What came next Aug 21, 2026 Insider · 1 person Insiders: 2 sales (~$66K) Oct 26, 2026 Company filing · Form 8-K · Listing notice Received a notice from its stock exchange “On October 26, 2026, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1).” Nov 16, 2026 Company filing · Form 8-K · Results Reported its results
Nov 16, 2026